Aurobindo Pharma receives US FTC approval for Lannett acquisition
Aurobindo Pharma · Pharmaceuticals & Biotechnology
Key highlights
- Aurobindo Pharma USA Inc., a wholly owned subsidiary, will acquire 100% membership interest in Lannett Company LLC from LANNETT SELLER HOLDCO, INC.
- Approval from the US Federal Trade Commission for the acquisition obtained on June 19, 2026.
- Transaction expected to close before the end of June 2026; updates will be provided to stock exchanges.
Why it's rated notable: The filing reports that FTC approval has been obtained for the Lannett acquisition under a definitive agreement, but it states no transaction value, so the level stays at medium.
Original filing
Disclosure Under Regulation 30 Of The SEBI (LODR) Regulations, 2015.
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Aerospace & Defense
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
More from Aurobindo Pharma
- Acquisition / mergerNotableAurobindo Pharma reports unaudited Q2 and half-year results ended September 30, 2026
- Acquisition / mergerNotableAurobindo Pharma subsidiary Apitoria completes acquisition of A1 Biochem Group business
- Acquisition / mergerNotableAurobindo Pharma completes acquisition of Lannett Company, USA
- Acquisition / mergerNotableAurobindo Pharma USA gets FTC approval to acquire Lannett Company LLC
Other acquisition / merger filings this fortnight
- IndiGrid Infrastructure Trust Q2 FY27 Earnings Conference Call Transcript Released
- Cubical Financial Services Ltd announces promoter reclassification post open offer
- Novus Loyalty Limited approves acquisition of AutoPe Payment Solutions via share swap
- Shish Industries Limited files Composite Scheme of Amalgamation proposal
- Jubilant Ingrevia Limited updates on acquisition of 40% stake in Zettaone Technologies
- NHC Foods approves quarter results, 99.98% Sachmaas Foods investment, two appointments
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.